Novo Nordisk sheds billions in value on obesity data
Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year according to IQVIA data and has been projected to top $100 million or more in some models, driven by the benefits that obesity drugs deliver beyond weight loss such as reduced cardiovascular risk.
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
Las acciones de la farmaceútuca danesa Novo Nordisk A/S registraron la mayor caída de su historia tras informar resultados ...
1don MSN
Evan David Seigerman, BMO managing director, joins 'Fast Money' to discuss Novo sinking on its obesity drug data.
Stocks traded sharply higher Friday as a key inflation measure came in lower than expected. The Dow Jones Industrial Average ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback